Letermovir for the compassionate therapeutic use of cytomegalovirus infection.

Purpose: Data on the efficacy, dosing and safety of letermovir for the compassionate therapeutic use of CMV infections are limited.

Methods: Clinical and virological efficacy of letermovir was assessed in a retrospective single-centre study of patients who received letermovir for the compassionate therapeutic use of CMV infections.

Results: Letermovir initiation yielded prompt treatment response in 7 out of 9 patients (77.